Evidence map›Paper›PMID 40880890›Full record

ReviewFrontiers in allergy2025

Prediction of food allergy reaction severity: biomarkers and host factors.

David J Fitzhugh

Abstract readReview
In one paragraph

Review in Frontiers in allergy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

David J FitzhughAllergy Partners of Chapel Hill, Chapel Hill, NC, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Prediction of food allergy reaction severity remains a challenging clinical dilemma, with no single biomarker or patient factor serving as a definitive predictor. Clinically, being able to accurately estimate future reaction severity would be a key advancement in terms of risk-stratifying patients who might most benefit from specific immunotherapy, anti-IgE therapy, or at minimum, ensuring this population always has autoinjectable epinephrine. This mini-review explores advancements in two key domains: biomarkers and host factors. Biomarker studies highlight the predictive limitations of IgE sensitization levels, while emerging tools such as basophil activation tests (BAT) and bead-based epitope assays (BBEA) are promising but are not yet in widespread use. Specifically, BAT demonstrates superior discriminatory power for severe peanut and baked egg reactions, whereas Arah2 component level above 1.4 kU/L suggest a more severe peanut allergy phenotype. Host factors, including comorbid conditions, age, and behavioral variables, further complicate severity prediction. While asthma has frequently been assumed to be involved in more severe reactions, recent meta-analyses refute this association unless asthma is poorly controlled. Similarly, a history of anaphylaxis does not reliably predict future reaction severity. Age emerges as a significant variable, with adolescents through the fourth decade of life displaying a higher risk for severe reactions. Additionally, cofactors such as exercise, alcohol, and certain medications may modulate reaction severity, albeit with varying degrees of evidence. Despite these advances, significant knowledge gaps remain in predicting reaction severity with high confidence. The future likely lies in a multifactorial approach. Understanding the interplay of biomarkers and host factors will be crucial in developing more accurate predictive models, ultimately enhancing food allergy management and patient safety.

Indexed as

anaphylaxisbasophil activating test (BAT)biomarkerscomponent resolved allergy diagnosticsfood allergy severity

Identifiers

PMID40880890
PMCPMC12380843

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.